BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Stock analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for BioHarvest Sciences in a research report issued to clients and investors on Tuesday, April 8th. HC Wainwright analyst A. Dayal forecasts that the company will earn ($0.10) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q3 2025 earnings at ($0.05) EPS and FY2029 earnings at $1.15 EPS.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The company had revenue of $7.17 million during the quarter, compared to the consensus estimate of $7.24 million.
Separately, Maxim Group assumed coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They issued a "buy" rating and a $12.00 target price on the stock.
Get Our Latest Analysis on BioHarvest Sciences
BioHarvest Sciences Stock Up 4.8 %
Shares of NASDAQ:BHST traded up $0.27 during midday trading on Wednesday, reaching $5.88. The company's stock had a trading volume of 88,728 shares, compared to its average volume of 11,905. BioHarvest Sciences has a 12-month low of $5.49 and a 12-month high of $7.38. The stock has a market capitalization of $96.58 million, a price-to-earnings ratio of -4.71 and a beta of 0.84. The business has a 50 day moving average of $5.73.
Institutional Investors Weigh In On BioHarvest Sciences
A hedge fund recently bought a new stake in BioHarvest Sciences stock. TD Waterhouse Canada Inc. purchased a new stake in shares of BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,042 shares of the company's stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned 0.07% of BioHarvest Sciences as of its most recent SEC filing.
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
See Also
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
